AURX.US Nuo Therapeutics Inc

Healthcare Biotechnology USA Stocks
1.09 USD
Close of Nov 12, 2026
0.7700 2.36
Market cap
USD 52.8M
P/E
-
P/B
41.78x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AURX.US undervalued?

Graham number

The Graham number of Nuo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nuo Therapeutics Inc fundamental analysis

No fundamental analysis for Nuo Therapeutics Inc yet.

Nuo Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nuo Therapeutics Inc

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physician…

Full company profile